Biohaven — Third Quarter 2026 Earnings Summary

Biohaven received FDA acceptance for its resubmitted new drug application for Vyglxia (troriluzole) in spinocerebellar ataxia, with a user fee goal date set for the first quarter of 2027. The company secured exclusive global licensing agreements, including a $400 million deal with SK Biopharmaceuticals for its Kv7 ion channel platform and a partnership with Ono Pharmaceutical for its MoDE IgG degrader portfolio in Asia. While a partial clinical hold was placed on new enrollment for opakalim (BHV-7000) pending nonclinical safety data, the pivotal RISE 3 trial remains on track for topline results in the second half of 2026. Biohaven reported a net loss of $129.3 million for the third quarter of 2026, driven by research and development expenses, while maintaining a cash position of approximately $164 million.